✖


Jump to content

Ново Нордич

(Перенаправлено из Novo Nordisk A/S )

Novo Nordisk A/S.
Тип компании Публичный
Промышленность Фармацевтические препараты , здравоохранение
Основан 21 декабря 1923 года ; 100 лет назад ( 1923-12-21 )
Штаб -квартира
Мешки меч
,
Дания
Ключевые люди
Продукция
Доход Увеличивать 232,3 млрд . Кр .
Увеличивать 102,6 млрд. DKK (2023)
Увеличивать 83,68 млрд. Кр.
Общие активы Увеличивать 314,5 млрд. Кр.
Общий капитал Увеличивать 106,6 млрд. DKK (2023)
Владелец Novo Holdings A/S (28%)
Количество сотрудников
Увеличивать 64,319 (конец 2023 г.)
Веб -сайт Novonordisk .с
Сноски / ссылки
[ 1 ] [ 2 ]
Бывший логотип

Novo Nordisk A/S - датская многонациональная фармацевтическая компания со штаб -квартирой в Bagsværd [ 3 ] с производственными средствами в девяти странах и филиалах или офисах в пяти странах. Novo Nordisk контролируется большинством акционеров Novo Holdings A/S, который владеет приблизительно 28% своих акций и большинством (77%) своих акций. [ 4 ]

Novo Nordisk производит и рынки фармацевтические продукты и услуги, в частности, диабета и устройства. лекарства от [ 5 ] Его основным продуктом является лечение лекарственного средства , используемое для лечения диабета под названием брендов Ozempic, Rybelsus и ожирением под брендом Wegovy. [ 6 ] Novo Nordisk также участвует в лечении гемостаза , гормональной терапией роста и заместительной гормональной терапией . Компания зарабатывает несколько наркотиков под различными брендами, включая Levemir , Tresiba , Novolog , Novolin R, Novoseven , Novoeight и Victoza . [ 1 ]

Novo Nordisk работает более 48 000 человек во всем мире, и в 168 странах продает свои продукты. [ 7 ] Корпорация была создана в 1989 году благодаря слиянию двух датских компаний, которые датируются 1920 -х годов. Логотип Novo Nordisk - это APIS Bull , одно из священных животных древнего Египта , обозначаемого иероглифом. Novo Nordisk является полным членом Европейской федерации фармацевтической промышленности и ассоциаций (EFPIA). [ 8 ]

Компания заняла 25 -е место среди лучших компаний Fortune 100 для работы в 2010 году и впоследствии заняла 72 -е место в 2014 году и 73 -е место в 2017 году. [ 9 ] [ 10 ] [ 11 ] В январе 2012 года Novo Nordisk был назван самой устойчивой компанией в мире компанией Business Magazine Corporate Knights , в то время как побочная компания Novozymes была названа четвертой. [ 12 ] Это лидер в индексе FTSE4Good и единственная европейская компания в первой десятке. [ 13 ] Novo Nordisk является крупнейшей фармацевтической компанией в Дании. [ 14 ] Novo Nordisk Рыночная капитализация превысила ВВП внутренней экономики Дании в 2023 году, и она является самой высокой ценной компанией в Европе. [ 15 ]

История

[ редактировать ]

1923

[ редактировать ]

Nordisk InsulinLaboratorium выдвигает производство инсулина. [ 16 ]

1982–1994

[ редактировать ]

Компания установила свое присутствие в Соединенных Штатах в 1982 году. [ Цитация необходима ]

В 1986 году Novo Industri A/S приобрела Ferrosan Group, которая теперь названа «Novo Nordisk Pharmatech A/S».

В 1989 году Novo Industry A/S (Novo Therapeutic Laboratory) и Nordisk Gentofte A/S (лаборатория Nordic Insulin) объединились, чтобы стать Novo Nordisk A/S, крупнейшим в мире производителем инсулина с штаб -квартирой в Багсвара, Копенгаген . [ 17 ]

В 1991 году Novo Nordisk Engineering (ныне nne A/S) в течение многих лет работала в качестве собственных консультантов в Novo Nordisk, чтобы предоставить стандартные инженерные услуги (сквозные инженерные компании) для компаний по производству фармацевтики. [ 18 ]

In 1994, Novo Nordisk's existing information technology units was spun out as NNIT A/S. The company was converted into a wholly owned aktieselskab in 2004[19] In March 2015, NNIT was floated on the Nasdaq Nordic.

2000–2018

[edit]

Novo's enzymes business, Novozymes A/S, was spun-out in 2000.[20]

Headquarters of Novo Nordisk USA, located in Plainsboro Township, New Jersey

Novo acquired Xellia for $700 million in 2013.[21]

The same year, Novo Nordisk USA moved into new headquarters offices in Plainsboro Township, New Jersey, by way of extensively renovating abandoned premises. This action served to consolidate several facilities that the company had previously had in Plainsboro.[22]

In 2015, the company announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate.[23]

In January 2018, Reuters reported that Novo had offered to acquire Ablynx for $3.1 billion - having made an unreported offer in mid-December for the company.[24] However, the Ablynx board rejected this offer the same day, explaining that the price undervalued the business.[24] Ultimately Novo lost out to Sanofi who bid $4.8 billion. Later, in the same year, the company announced it would acquire Ziylo for around $800 million.[25]

2020–present

[edit]

In March 2020, Novo volunteers started testing samples for SARS-CoV-2 with RT-qPCR equipment in the ongoing coronavirus pandemic to increase available test capacity.[26] In June, the business announced it would acquire AstraZeneca's spin-off Corvidia Therapeutics for an initial sum of $725 million (up to a performance-related maximum of $2.1 billion), boosting its presence in cardiovascular diseases.[27] In November, the company announced it would acquire Emisphere Technologies for $1.8 billion, gaining control of a pill-based treatment for diabetes.[27][28] In December, Novo announced it would acquire Emisphere Technologies for $1.35 billion.[29]

In November 2021, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share).[30]

In September 2022, Novo agreed to acquire Forma Therapeutics for $1.1 billion with the intent to expand its sickle cell disease and rare blood disorders portfolio.[31]

By 2022 the popularity of Novo's Wegovy and Ozempic for weight loss was so great as to significantly increase growth of the entire economy of Denmark. In fact, two-thirds of Denmark's overall economic growth in 2022 was attributed to the pharmaceutical industry.[32]

The company's profits increased by 45% year over year in the first half of 2023.[6] Most of the growth occurred from its weight loss drugs, Wegovy and Ozempic, which accounted for 55% of the company's 2023 revenue.[33]

In August 2023, Novo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1 billion[34] and Embark Biotech for up to $500 million.[35] In October 2023, the company announced it would acquire ocedurenone—an experimental drug for uncontrolled hypertension and potentially beneficial in treating cardiovascular and kidney diseases—from KBP Biosciences for $1.3 billion.[36]

In November 2023, Novo Nordisk announced investment of €2.1 billion in a French production facility to increase the production capacity and manufacturing of its popular anti-obesity medication.[37]

In February 2024, parent company Novo Holdings A/S agreed to acquire Catalent for $16.5 billion. On completion, Novo Nordisk said it would acquire three manufacturing facilities from its parent for $11 billion to scale up production to meet the demand of Wegovy and Ozempic.[38][39]

In March 2024 Novo Nordisk reached $604B market cap and became 12th most valuable company in the world. Company's stock jumped to a record high after early trial data showed positive results for its new experimental weight loss pill Amycretin.[40] The company also announced it would acquire Cardior Pharmaceuticals and its cardiovascular disease portfolio for up to $1.1 billion.[41] In May, the company announced it would acquire Austrian fluid management service business, Single Use Support.[42]

In June 2024 the company announced plans to build a new production plant in Clayton, North Carolina, at a cost of $4.1 billion. It will be the company's fourth in the state of North Carolina and used for production of semaglutide products Ozempic and Wegovy.[43]

Acquisition history

[edit]
Novo Nordisk acquisitions

Toxicogenomics

[edit]

Novo Nordisk is involved in government funded collaborative research projects with other industrial and governmental partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[44][45] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of European Federation of Pharmaceutical Industries and Associations and the European Commission.[46]

Diabetic work

[edit]
Novo Nordisk's largest manufacturing plant located in Kalundborg, Denmark

Novo Nordisk founded the World Diabetes foundation to save the lives of those affected by diabetes in developing countries and supported a UN (United Nations) resolution to fight diabetes, making diabetes the only other disease along with HIV / AIDS that the UN has a commitment to combat.[47]

Diabetic treatments account for 85% of Novo Nordisk's business. Novo Nordisk works with doctors, nurses, and patients, to develop products for self-managing diabetes conditions. The DAWN (Diabetes Attitudes, Wishes and Needs) 2001 study was a global survey of the psychosocial aspects of living with diabetes. It involved over 5,000 people with diabetes and almost 4,000 care providers.[48] This study was designed to identify barriers to optimal health and quality of life. A follow-up study completed in 2012 involved more than 15,000 people living with, or caring for, those with diabetes. In response to British findings, a National Action Plan (NAP) was developed, with a multidisciplinary steering committee, to support the delivery of individualised person-focused care in the United Kingdom. The NAP seeks to provide a holistic approach to a diabetic treatment for patients and their families.[49]

The i3-diabetes programme is a collaboration between the King's Health Partners, one of only six Academic Health Sciences Centres (AHSCs) in England, and Novo Nordisk. The programme is a five-year collaboration designed to deliver personalised care that will lead to improved outcomes for people living with diabetes, and more efficient and effective ways of caring for people with diabetes.[50][51]

Diabetic support advocacy

[edit]

Novo Nordisk have sponsored the International Diabetes Federation's Unite for Diabetes campaign.[52]

In March 2014, Novo Nordisk announced a partnership program entitled ‘Cities Changing Diabetes,’ which entails combating urban diabetes. Partnership includes University College London (UCL) and supported by Steno Diabetes Center, as well as a range of local partners including healthcare professionals, city authorities, urban planners, businesses, academics and community leaders.[53]

A November 2014 newspaper article, suggested that a recent medical research breakthrough at Harvard University (creating insulin-producing cells from embryonic stem cells) could potentially put Novo Nordisk out of business. Dr Alan Moses, the chief medical officer of Novo Nordisk, commented that the biology of diabetes is incredibly complex, but also that Novo Nordisk's mission is to alleviate and cure diabetes. If this new medical advance "...meant the dissolution of Novo Nordisk, that'd be fine."[54]

In September 2023, Novo Nordisk and UNICEF announced a multi-year expansion of their collaboration to address childhood overweight and obesity.[55][56]

Research and pipeline

[edit]

Novo Nordisk was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies.[57] In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis.[58]

In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on “transformational biological and technological innovation”.[59]

Controversies

[edit]

In 2010, Novo Nordisk breached the code of conduct for Association of the British Pharmaceutical Industry (ABPI), by failing to provide information about side-effects of Victoza and by promoting Victoza prior to being granted market authorisation.[60]

In 2013, Novo Nordisk had to pay back 3.6 kr. billion to the Danish tax authorities due to transfer mispricing.[61]

In March 2013, a debate emerged in which scientists questioned whether the incretin class of diabetic medications – the class to which Victoza belongs – had an increased risk of side effects in the pancreas such as pancreatitis and pancreatic cancer. It was concluded that data currently available did not confirm these concerns.[62]

In October 2013, batches of NovoMix 30 FlexPen and Penfill insulin were recalled in some European countries as their analysis had shown that a small percentage of the products in these batches did not meet the specifications for insulin strength.[63]

In September 2017, Novo Nordisk agreed to pay $58.7 million to end a United States Department of Justice probe into the lack of FDA disclosure to doctors about the cancer risk for their diabetic drug, Victoza.[64]

In March 2023, Novo Nordisk was suspended from the ABPI for a period of two years, for engaging in misleading marketing practices that amounted to "bribing health professionals with inducement to prescribe".[65] This is only the eighth time in the last 40 years that ABPI sanctioned a member organization.[66] Consequently, the Royal College of General Practitioners[67] and the Royal College of Physicians[68] ended their corporate partnerships as it would be in breach of their ethical guidance. The Novo Nordisk UK General Manager, Pinder Sahota, chose to resign as President of the ABPI prior to the suspension.[66]

On February 2, 2024 The United States Judicial Panel on Multidistrict Litigation ordered that 55 lawsuits pending in federal courts be consolidated into a multidistrict litigation. The majority of the cases were against Novo Nordisk, but some were brought against Eli Lilly. The Ozempic Lawsuits allege gastroparesis ileus and other injuries caused by GLP-1 RAS. The Case is known as MDL No. 3094 In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation. As of August 6, 2024 there were 235 active Ozempic lawsuits.

In 2024 Novo Nordisk drug pricing in the US has been a target of lawmakers, including Senator Bernie Sanders and the Senate committee Health, Education, Labor and Pensions (HELP). The committee investigation found Novo Nordisk's drug Ozempic priced for $969 per month in the US, compared to $155 in Canada and $59 in Germany. Its weight-loss drug Wegovy is priced for $1,349 per month in the US compared to $140 in Germany and $92 in the UK.[33] In July 2024, US President Joe Biden joined Sanders in stating "Novo Nordisk and Eli Lilly must stop ripping off Americans with high drug prices."[69]

Sponsorships and pitchpeople

[edit]
Charlie Kimball at the 2015 Indianapolis 500

Novo Nordisk has sponsored athletes with diabetes, such as Charlie Kimball in auto racing and Team Novo Nordisk in road cycling.[70]

As of the 2010s, Anthony Anderson (star of Black-ish) serves as a pitchman for Novo Nordisk, and featured in the company's television advertisements which aired in the US.[71]

See also

[edit]

References

[edit]
  1. ^ Jump up to: a b "Annual Report 2023" (PDF). Novo Nordisk. Archived from the original (PDF) on 31 January 2024. Retrieved 1 February 2024.
  2. ^ "Form 6-K". U.S. Securities and Exchange Commission. 3 August 2022.
  3. ^ "Who we are". www.novonordisk.com. Retrieved 28 September 2021.
  4. ^ "Novo Nordisk share and ownership structure". Retrieved 24 August 2023.
  5. ^ "Novo Nordisk sees slower 2020 growth with US insulin prices pressured". CNBC. 5 February 2020. Retrieved 20 April 2020.
  6. ^ Jump up to: a b Nelson, Eshe (30 August 2023). "Novo Nordisk Tilts G.D.P. In Denmark". The New York Times. p. B1. ISSN 0362-4331. Retrieved 5 October 2023.
  7. ^ "Annual Report 2021" (PDF). Novo Nordisk. Archived from the original (PDF) on 7 February 2022. Retrieved 13 March 2022.
  8. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 16 September 2008. Retrieved 25 August 2008.
  9. ^ "100 Best Companies to Work For 2010: Full list". Fortune. 2010.
  10. ^ "Fortune 100 Best Companies to Work For® 2017". Great Place To Work®. Retrieved 26 June 2024.
  11. ^ Wasserman, Emily (16 January 2024). "Novo Nordisk Named on the 2014 FORTUNE 100 Best Companies to Work For® List for Sixth Consecutive Year". Fierce Pharma. Retrieved 26 June 2024.
  12. ^ read, Bart King Published 8 years ago About a 2 minute (27 January 2012). "Novo Nordisk Ranked World's Most Sustainable Corporation". Sustainable Brands. Retrieved 20 April 2020.{{cite web}}: CS1 maint: numeric names: authors list (link)
  13. ^ "Corporate Governance and the FTSE4Good Index: A Closer Look".
  14. ^ Stegger, Clara (2 December 2022). "Første danske virksomhed nogensinde: Novo Nordisk rammer gigantisk beløb". Finans (in Danish). Retrieved 18 January 2023.
  15. ^ Wienberg, Christian (9 August 2023). "Novo's Value Surpasses Denmark GDP After Obesity Drug Boost". Bloomberg News.
  16. ^ "Insulin 100 years".
  17. ^ "Our History". www.novonordisk.com. Archived from the original on 8 July 2019. Retrieved 24 February 2019.
  18. ^ "About us - learn more about NNE".
  19. ^ "NNIT History". www.nnit.com. Archived from the original on 8 July 2019. Retrieved 24 February 2019.
  20. ^ "Our history". www.novozymes.com. Retrieved 1 September 2023.
  21. ^ "Novo A/S acquires Xellia Pharmaceuticals for US$ 700 million". www.businesswire.com. 21 May 2013.
  22. ^ De Poto, Tom (18 April 2013). "Novo Nordisk transforms vacant building into U.S. headquarters". The Star-Ledger. Newark, New Jersey.
  23. ^ "Novo Nordisk Joins Ablynx in Up-to-$399M+ Nanobody® Alliance". 25 November 2015.
  24. ^ Jump up to: a b "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". 8 January 2018. Archived from the original on 27 November 2018 – via uk.reuters.com.
  25. ^ "Novo Nordisk Acquires Ziylo in Possible $800 Million-Plus Deal". BioSpace. 17 August 2018.
  26. ^ Mølsted, Henning (28 March 2020). "Dual shift at Novo now testing Corona samples" (in Danish). Ingeniøren.
  27. ^ Jump up to: a b "Reuters". Reuters.
  28. ^ "Novo Nordisk Acquires Emisphere Tech in $1.8 Billion Deal | BioSpace". 6 November 2020.
  29. ^ "Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion | BioSpace". 8 December 2020.
  30. ^ "Novo Nordisk to Acquire Dicerna | BioSpace". 18 November 2021.
  31. ^ Roy, Mrinalika; Jacobsen, Stine (1 September 2022). "Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal". Reuters.
  32. ^ Nelson, Eshe (28 August 2023). "How Ozempic and Weight Loss Drugs Are Reshaping Denmark's Economy". The New York Times. ISSN 0362-4331. Retrieved 25 December 2023.
  33. ^ Jump up to: a b Dunleavy, Kevin (17 June 2024). "Novo Nordisk CEO Jorgensen agrees to testify before Senate over U.S. pricing of semaglutide products". Fierce Pharma. Retrieved 28 June 2024.
  34. ^ Constantino, Annika Kim (10 August 2023). "Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion". CNBC. Retrieved 11 August 2023.
  35. ^ "Novo Bolsters Obesity Pipeline with Potential $500M Embark Biotech Buy". 30 August 2023.
  36. ^ Roush, Ty (16 October 2023). "Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal". Forbes.
  37. ^ "Denmark's Novo Nordisk invests €2.1 billion in France". Euronews Business. 24 November 2023.
  38. ^ Gilbert, Daniel (5 February 2024). "Novo Nordisk buys manufacturing power as it seeks to ramp up Wegovy". The Washington Post.
  39. ^ Constantino, Annika Kim (5 February 2024). "Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply". CNBC.
  40. ^ Gilchrist, Karen (8 March 2024). "Novo Nordisk market cap surpasses Tesla on new obesity pill trial data". CNBC. Retrieved 8 March 2024.
  41. ^ "Novartis, Ono Latest to Announce Billion-Dollar M&A Deals". 5 March 2024.
  42. ^ "Novo Acquires Majority Stake in Austrian Life Sciences Tools Company". 15 May 2024.
  43. ^ Dunleavy, Kevin (24 June 2024). "Novo Nordisk reveals plan to build mammoth $4.1B plant in North Carolina to help produce Ozempic, Wegovy". Fierce Pharma. Retrieved 26 June 2024.
  44. ^ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
  45. ^ "InnoMed PredTox Member Organizations". Archived from the original on 26 September 2008. Retrieved 25 August 2008.
  46. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 15 October 2009. Retrieved 25 August 2008.
  47. ^ "World Diabetes Foundation website". Archived from the original on 19 September 2008. Retrieved 25 August 2008.
  48. ^ "Study Results". DAWN Study. Novo Nordisk. Retrieved 11 July 2016.
  49. ^ Funnell, M. M. (2006). "The Diabetes Attitudes, Wishes, and Needs (DAWN) Study". Clinical Diabetes. 24 (4): 154–155. doi:10.2337/diaclin.24.4.154.
  50. ^ "i3-diabetes programme". i3diabetes.org.uk. Archived from the original on 14 December 2014.
  51. ^ "Насколько эффективна система эсмиссии диабета?" Полем Reviewsmemo.com.
  52. ^ «Ново Нордиск в Объединенных усилиях в день мира диабета» . Worlddiabetesday.org.
  53. ^ «Ново Нордиск запускает« города, меняющие диабет », чтобы бороться с городским диабетом» . Ново Нордиск . Получено 25 апреля 2014 года .
  54. ^ Роланд, Дениз (24 ноября 2014 г.) Инсулин Пионер видит, как конец в поле зрения для диабета - и сам по себе ежедневный телеграф, извлечен 25 ноября 2014 г.
  55. ^ «Novo Nordisk и Unicef ​​расширяют свое сотрудничество, чтобы помочь предотвратить избыточный вес и детское ожирение» [Novo Nordisk и Unicef ​​Collaboration, чтобы помочь предотвратить ускорение детства и ожирение] (по -испански). Europa Press. 25 сентября 2023 года.
  56. ^ Булик, Бет Снайдер (11 декабря 2019 г.). «Ново Нордиск присоединяется к ЮНИСЕФ в глобальных и местных усилиях по прекращению детского ожирения» . Жесткая фарма .
  57. ^ «Биофармацевтические исследования», Novo Nordisk Corporation » . Novonordisk.com . Получено 29 ноября 2011 года .
  58. ^ Ламм, Грег (4 сентября 2014 г.). «Novo Nordisk сокращает рабочие места в Seattle Research Facital» . bizjournals.com . Получено 27 октября 2014 года .
  59. ^ «Novo Nordisk проливает 400 сотрудников, поскольку он переориентирует усилия по исследованиям и разработкам» . Финансовые времена. 18 сентября 2018 года . Получено 2 ноября 2018 года .
  60. ^ «Novo Nordisk Limited, Eli Lilly and Company Limited, Grünenthal Ltd и Napp Pharmaceuticals Limited названы в рекламе» . Рецептурные лекарства Кодекс практического управления (PMCPA) . Получено 7 февраля 2011 года .
  61. ^ «Так налоговые снимки Novo Nordisk за 3,6 миллиарда» . Получено 5 февраля 2013 года .
  62. ^ Funch, D.; Gydesen, H.; Tornøe, K.; Major-Pedersen, A.; Чан, Ка (2014). «Перспективная, основанная на претензиях оценку риска панкреатита и рака поджелудочной железы с лираглутидом по сравнению с другими антидиабетическими препаратами» . Диабет, ожирение и метаболизм . 16 (3): 273–275. doi : 10.1111/dom.12230 . PMC   4237552 . PMID   24199745 .
  63. ^ «Медицинское предупреждение: партии Novomix 30 Flexpen и Penfill, чтобы вспомнить» . Диабет Великобритания . Получено 25 апреля 2014 года .
  64. ^ Маклафлин, Дэвид; Харрис, Эндрю М .; ФИЛИ (6 сентября 2017 г.). «Novo Nordisk зарекомендовал себя по иску на Victoza за 58,65 миллиона долларов» . Bloomberg News . Получено 6 сентября 2017 года .
  65. ^ Дэвис, Никола (16 марта 2023 г.). «Фирма, стоящая за Wegovy похудения, приостановлена ​​от британской торговой ассоциации» . Хранитель .
  66. ^ Jump up to: а беременный Гровер, Натали (16 марта 2023 г.). «Ново Нордиск отстранен от британской лоббистской группы» . Рейтер.
  67. ^ «Заявление RCGP о партнерстве с Novo Nordisk» .
  68. ^ Дас, Шанти; Ungoed-Thomas, Джон (18 марта 2023 г.). « Skinny Jab» наркомана, столкнулась с свежими запросами после «серьезных нарушений» кода промышленности » . Хранитель .
  69. ^ Сандерс, президент Джо Байден и Сен Берни. «Президент Байден: Ново Нордиск, Эли Лилли должен перестать сорвать американцев с высокими ценами на наркотики» . USA сегодня . Получено 11 июля 2024 года .
  70. ^ Булик, Бет (28 сентября 2016 г.). «Novo Nordisk и Driver Indy Charlie Kimball Drive Partnership до 100 раций и подсчета» . Жесткая фарма . Получено 21 июня 2018 года .
  71. ^ «История диабета Энтони Андерсона 2 типа | www.getRealAboutdiabetes.com . Получено 8 мая 2024 года .
[ редактировать ]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Novo_Nordisk&oldid=1245422665"
Arc.Ask3.Ru: конец переведенного документа.
Arc.Ask3.Ru
Номер скриншота №: 74a8d2bc3035ffb02b3798809abea8f4__1726169460
URL1:https://arc.ask3.ru/arc/aa/74/f4/74a8d2bc3035ffb02b3798809abea8f4.html
Заголовок, (Title) документа по адресу, URL1:
Novo Nordisk - Wikipedia
Данный printscreen веб страницы (снимок веб страницы, скриншот веб страницы), визуально-программная копия документа расположенного по адресу URL1 и сохраненная в файл, имеет: квалифицированную, усовершенствованную (подтверждены: метки времени, валидность сертификата), открепленную ЭЦП (приложена к данному файлу), что может быть использовано для подтверждения содержания и факта существования документа в этот момент времени. Права на данный скриншот принадлежат администрации Ask3.ru, использование в качестве доказательства только с письменного разрешения правообладателя скриншота. Администрация Ask3.ru не несет ответственности за информацию размещенную на данном скриншоте. Права на прочие зарегистрированные элементы любого права, изображенные на снимках принадлежат их владельцам. Качество перевода предоставляется как есть. Любые претензии, иски не могут быть предъявлены. Если вы не согласны с любым пунктом перечисленным выше, вы не можете использовать данный сайт и информация размещенную на нем (сайте/странице), немедленно покиньте данный сайт. В случае нарушения любого пункта перечисленного выше, штраф 55! (Пятьдесят пять факториал, Денежную единицу (имеющую самостоятельную стоимость) можете выбрать самостоятельно, выплаичвается товарами в течение 7 дней с момента нарушения.)